newsfilter
← Latest News
GlobeNewswire·

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that